Holiday Hot Stock Watch - GXPI ison the Move

Stocks to Watch: Gemini Explorations, Inc. (OTC BB:GXPI), Skins Inc.  (OTC BB:SKNN) , Sciele Pharma, Inc. (Nasdaq:SCRX) , WorldWater & Solar Technologies Corp. (OTC BB:WWAT) , Carrington Laboratories, Inc. (OTC BB:CARN)

Featured Stock: Gemini Explorations, Inc

(OTC BB: GXPI)

Current Price: (0.16)

www.WallStreetStockReview.com

Gemini Explorations Inc. Receives Joint Venture Proposal to Expand the Los Chorros Gold Project

CALGARY, AB-- Nov 20, 2007 -- Gemini Explorations Inc. ("Gemini") (OTC BB:GXPI.OB - News) is pleased to report that it has received a joint venture proposal from concession holders adjoining the Los Chorros Gold Mine. The proposal would expand Gemini's land position and increase the scale of the Los Chorros Gold project. Gemini had received a number of joint processing proposals and has now expanded those proposals to include ownership in the adjoining concessions. Gemini's plans are to build a modern processing facility at Los Chorros with far greater recovery rates of the gold and other precious metals present. The new joint ownership and processing proposals in the adjoining mine concessions present an excellent opportunity for Gemini to increase revenue, expand mine life and accelerate the capital recovery costs of modernizing the Los Chorros mine. Gemini reported on November 5, 2007 that a 100 tonne per day production rate would produce US$1,080,280 monthly and over US$12,900,000 annually. These estimates are based on US$730 per ounce gold with US$200 per ounce operating and production costs netting US$530 per ounce.

Contact:

     Contact:

     Michael Hill

     President

     Gemini Explorations Inc.

     Suite 103, 240-11th Ave SW

     Calgary, AB T2R 0C3

     http://www.geminiexploration.com/

     email: info@geminiexploration.com

Source: Gemini Explorations Inc.

For an in-depth analyst report, please visit: www.WallStreetStockReview.com

Skins Inc.

(OTC BB:SKNN)

Current Price (0.94)

http://www.wallstreetstockreview.com/

NEW YORK--Nov 21--Skins Inc. (OTCBB: SKNN - News), a developer of a revolutionary, patented, two-part interchangeable footwear structure, today announced that the company will be distributing a newsletter for investors and other parties interested in the ongoing developments at Skins Inc. The newsletter, which will be emailed to subscribers and also posted on the company’s website, skinsfootwear.com, will include product developments, features on Skins retailers, news releases, and updates from the company’s Chairman, Michael J. Rosenthal.          Skins Inc. created and is continuing to develop an innovative and patented two-part, interchangeable footwear structure consisting of outer collapsible "Skins" and an inner holistic orthopedic support section called the "Bone." The design allows consumers to purchase one inner section, the Bone, and numerous outer Skins, resulting in multiple style variations from the same pair of quality Bones, always with the same feel and fit no matter which Skin is being worn. Skins' objective is to create a new attire concept that allows and encourages consumers to frequently change their footwear, while experiencing equal comfort in all designs of shoes. This uniquely positions the Skins concept between footwear and apparel industries. For more information, visit http://www.skinsfootwear.com/.

Sciele Pharma, Inc.

(Nasdaq:SCRX)

Current Price (21.00)

http://www.wallstreetstockreview.com/

ATLANTA--Nov 21--Sciele Pharma, Inc. (NASDAQ:SCRX - News), a specialty pharmaceutical company, today announced that Darrell Borne, Chief Financial Officer, will make a presentation at the 19th Annual Piper Jaffray Health Care Conference at the Pierre Hotel in New York City on Wednesday, November 28, 2007, at 4:30 p.m. Eastern Time.                 Sciele Pharma, Inc. is a pharmaceutical company specializing in sales, marketing and development of branded prescription products focused on Cardiovascular/Diabetes, Women’s Heath and Pediatrics. The Company’s Cardiovascular/Diabetes products treat patients with high cholesterol, hypertension, high triglycerides, unstable angina and Type 2 diabetes; its Women’s Health products are designed to improve the health and well-being of women and mothers and their babies; and its Pediatric products treat allergies, asthma, coughs and colds, and attention deficit and hyperactivity disorder (ADHD). Founded in 1992 and headquartered in Atlanta, Sciele Pharma employs more than 900 people. The Company’s success is based upon placing the needs of patients first, improving health and quality of life, and implementing its business platform-an Entrepreneurial Spirit, Innovation, Speed of Execution, Simplicity and Teamwork.

WorldWater & Solar Technologies Corp.

(OTC BB:WWAT)

Current Price (1.73)

http://www.wallstreetstockreview.com/

EWING, N.J.--Nov 21--WorldWater & Solar Technologies Corporation (WWAT), developer and marketer of proprietary high-power solar systems announced today the introduction of WorldWater’s new “ACWA WATT Select Program,” offering solar systems to Association of California Water Agencies (ACWA) members at no investment cost and at energy prices equal to or below grid rates for 20 years or more. ACWA is a statewide association of public water agencies whose 440 members are responsible for about 90% of the water delivered in California.              WorldWater & Solar Technologies Corporation is a full-service, international solar electric engineering and water management company with unique, high-powered and patented solar technology that provides solutions to a broad spectrum of the world's electricity and water supply problems. For more information about WorldWater & Solar Technologies Corp., visit the website at www.worldwater.com.

Carrington Laboratories, Inc.

(OTC BB:CARN.OB)

Current Price (1.73)

http://www.wallstreetstockreview.com/

IRVING, Texas--Nov 21--Carrington Laboratories, Inc. (OTCBB:CARN - News), a research-based, biopharmaceutical and consumer products company, will hold its quarterly conference call to discuss third quarter results on Tuesday, November 27, 2007, at 4:30 p.m. Eastern Time (3:30 p.m. Central Time). Third quarter unaudited financial results will be released earlier the same day.                 Carrington Laboratories, Inc. is an ISO 9001-certified, research-based biopharmaceutical company currently utilizing naturally-occurring complex carbohydrates to:The webcast is also being distributed through the Thomson StreetEvents Network to both institutional and individual investors. Individual investors can listen to the call at www.fulldisclosure.com, Thomson/CCBN’s individual investor portal, powered by StreetEvents. Institutional investors can access the call via Thomson’s password-protected event management site, StreetEvents (www.streetevents.com).

WallStreetStockReview.com is owned and operated by Iron Consulting.

Verify all claims and do your own due diligence. Iron Consulting profiles are not a solicitation or recommendation to buy, sell or hold securities. Iron Consulting is not offering securities for sale. An offer to buy or sell can be made only with accompanying disclosure documents and only in the states and provinces for which they are approved. All statements and expressions are the sole opinion of the editor and are subject to change without notice. Iron Consulting is not liable for any investment decisions by its readers or subscribers. It is strongly recommended that any purchase or sale decision be discussed with a financial adviser, or a broker-dealer, or a member of any financial regulatory bodies. The information contained herein has been provided as an information service only. The accuracy or completeness of the information is not warranted and is only as reliable as the sources from which it was obtained. It should be understood there is no guarantee that past performance will be indicative of future results. Investors are cautioned that they may lose all or a portion of their investment in this or any other company. In order to be in full compliance with the Securities Act of 1933, Section 17(b),WallStreetStockReview.com is owned and operated by Iron Consulting. Iron Consulting www.ironconsultinginc.com has receive seventy two thousand dollars in 2006 and thirty six thousand in 2007 from Equity Alliance Intl. www.equityallianceir.com for a internet marketing program. Neither Iron Consulting nor any of its affiliates, or employees shall be liable to you or anyone else for any loss or damages from use of this e-mail, caused in whole or part by its negligence or contingencies beyond its control in procuring, compiling, interpreting, reporting, or delivering this Web Site or e-mail and any contents. Since Iron Consulting receives compensation and its employees or members of their families may hold stock in the profiled companies, there is an inherent conflict of interest in Iron Consulting statements and opinions and such statements and opinions cannot be considered independent. Iron Consulting and its management may benefit from any increase in the share prices of the profiled companies. Information contained herein contains "forward looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities and Exchange Act of 1934. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical facts and may be "forward looking statements". Forward looking statements are based on expectations, estimates and projections at the time the statements ar e made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Iron Consulting services are often paid for using free-trading shares. Iron Consulting may be selling shares of stock at the same time the profile is being disseminated to potential investors; this should be viewed as a definite conflict of interest and as such, the reader should take this into consideration.